The Business Research Company’s report on the Cardiac Biomarkers Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the cardiac biomarkers industry?
The rising prevalence of cardiovascular disorders is expected to propel the growth of the cardiac biomarker market going forward. Cardiovascular disorders are diseases that affect the heart and blood vessels and include conditions such as coronary artery disease, heart failure, and stroke. Cardiac biomarkers are released into the bloodstream in response to certain cardiovascular disorders, such as myocardial infarction (heart attack), heart failure, and arrhythmias, which can be measured using laboratory tests, and their levels can provide important diagnostic and prognostic information. For instance, in September 2024, according to the data published by the British Heart Foundation, a UK-based cardiovascular research charity, in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these conditions. These diseases are responsible for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Therefore, the rising prevalence of cardiovascular disorders is driving the growth of the cardiac biomarker market.
Access Your Free Sample of the Global Cardiac Biomarkers Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp
What is the estimated market size of the cardiac biomarkers sector by 2029, based on current forecasts?
The cardiac biomarkers market size has grown rapidly in recent years. It will grow from$18.99 billion in 2024 to $21.32 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increased healthcare expenditure, FDA approvals and regulatory support, aging population, awareness programs, high sensitivity troponin tests, increasing cardiovascular diseases
The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to “$36.51 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising burden of chronic diseases, growing emphasis on early disease detection, expansion of geriatric population, emerging markets development, focus on biomarker panels. Major trends in the forecast period include patient-centric healthcare models, ai and machine learning applications, digital health integration, technological innovations in biomarker discovery, multi-marker panels, liquid biopsy in cardiovascular medicine.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp
#Who are the top players in the cardiac biomarkers market?
Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics
#What are the major trends in the cardiac biomarkers market?
Technological advancements are a key trend gaining popularity in the cardiac biomarker market. Companies operating in the cardiac biomarker market are adopting new technologies to sustain their position in the market. For instance, in October 2023, Mindray’s China-based medical devices company launched new high-sensitivity cardiac biomarkers troponin I (hs-cTnI) and NT-proBNP to enhance the diagnosis and management of cardiovascular diseases (CVDs). The hs-cTnI biomarker plays a vital role in identifying myocardial injury, boasting an impressive detection rate and low imprecision, which makes it valuable for early screening and risk assessment in cases like Acute Coronary Syndrome (ACS). In contrast, NT-proBNP is a well-established marker for heart failure, supporting its detection and management while exhibiting high precision and minimal interference from frequently used heart medications. Together, these biomarkers significantly improve clinical decision-making in urgent cardiovascular care.
Which geography holds the highest cardiac biomarkers market share?
North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report
How do different segments contribute to the overall expansion of the cardiac biomarkers market?
The cardiac biomarkers market covered in this report is segmented –
1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications
4) By End User: Hospitals, Specialty Clinics
Subsegments:
1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels
2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels
3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels
4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels
5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels
6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234
How is the cardiac biomarkers market defined?
Cardiac biomarkers are chemicals released by heart into the blood when it is injured or under stress. It used for the detection and measurement of various cardiac vascular diseases.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
